Prostat Kanserinde İrreversibl Elektroporasyon
Özet
Prostat kanseri (PKa), erkeklerde dünya genelinde en sık teşhis edilen ikinci kanser türü olup, geleneksel radikal cerrahi ve radyoterapi yöntemlerinin erektil disfonksiyon, inkontinans ve rektal komplikasyon riskleri mevcuttur. Bu yan etkileri azaltmak ve aktif izlem protokollerinin getirdiği anksiyete ile biyopsi morbiditesini önlemek amacıyla fokal tedaviler geliştirilmiştir. İrreversibl Elektroporasyon (IRE), termal tabanlı ablasyon yöntemlerinin aksine, yoğun elektrik darbeleri kullanarak hücre zarında kalıcı nano-porlar oluşturan non-termal bir fokal tedavi tekniğidir. Bu mekanizma, hedef tümör dokusunu yok ederken üreter, rektum, üretra ve nörovasküler demet gibi kritik komşu anatomik yapıları korur. Yapılan Faz I ve II klinik çalışmalar, IRE prosedürünün yüksek dereceli yan etkilere yol açmadığını, hastaların kontinans ve potens oranlarını büyük ölçüde koruduğunu ve kısa-orta vadede başarılı onkolojik sonuçlar sunduğunu göstermektedir. Özellikle apikal yerleşimli lezyonlarda bile üretral sfinkter hasarı riski yaratmadan güvenle uygulanabildiği tespit edilmiştir. Bununla birlikte, uzun vadeli onkolojik verilerin yetersizliği nedeniyle Avrupa Üroloji kılavuzları bu yöntemi henüz deneysel bir klinik araştırma tedavisi olarak kabul etmektedir. Sonuç olarak IRE, yakın gelecekte PKa tedavisinde popülaritesini artıracak umut verici bir minimal invaziv alternatiftir.
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men globally, yet conventional radical treatments carry significant risks of complications such as erectile dysfunction, urinary incontinence, and rectal damage. To mitigate these side effects and avoid the anxiety associated with active surveillance protocols, focal therapies have emerged. Irreversible Electroporation (IRE) is a novel non-thermal focal ablation technique that applies high-voltage electrical pulses to induce permanent nano-pores in cell membranes, bypassing the thermal sinks of traditional methods. This unique mechanism effectively destroys tumor tissue while strictly preserving the scaffolding of vital adjacent structures, including the urethra, rectum, and neurovascular bundles. Phase I/II clinical trials demonstrate that IRE induces minimal morbidity, effectively maintains urinary continence and sexual potency, and achieves favorable short-to-medium-term oncological control. Recent data even highlights its safety in treating challenging apical lesions without compromising the urethral sphincter. However, due to the lack of long-term survival data, the 2021 European Association of Urology guidelines still classify IRE as an experimental approach restricted to clinical trials. Ultimately, IRE represents a promising, highly precise alternative that is poised to gain widespread popularity in localized prostate cancer management.
Referanslar
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. (2012). [online]. Website http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 2012. [accessed 12/09/2021].
Akin Y, Kose O, Gulmez H, León Mar R, Erturhan S, Nuri Gorgel S, et al. A novel surgical technique for extraperitoneal radical prostatectomy with using 3 trocars: Results after 154 cases. Arch Esp Urol. 2021;74:231-8.
Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. N Engl J Med. 2013;368:436–45.
Carlsson S, Sandin F, Fall K, Lambe M, Adolfsson J, Stattin P, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer. 2013;49:1588–99.
Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: Histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818–24.
Smeenge M, Mischi M, Laguna Pes MP, de la Rosette JJMCH, Wijkstra H. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol. 2011;29:581–7.
Karagiannis A, Varkarakis J. Irreversible Electroporation for the Ablation of Prostate Cancer. Curr Urol Rep. 2019;20:63.
Wagstaff PGK, de Bruin DM, van den Bos W, Ingels A, van Gemert MJC, Zondervan PJ, et al. Irreversible electroporation of the porcine kidney: Temperature development and distribution. Urol Oncol Semin Orig Investig. 2015;33:168.e1-e7.
Pech M, Janitzky A, Wendler JJ, Strang C, Blaschke S, Dudeck O, et al. Irreversible electroporation of renal cell carcinoma: A first-in-man phase i clinical study. Cardiovasc Intervent Radiol. 2011;34:132–8.
Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos R V, et al. Tumor ablation with irreversible electroporation. PLoS One. 2007;2:e1135.
Dunki-Jacobs EM, Philips P, Martin RCG. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg. 2014;218:179–87.
Dong S, Wang H, Zhao Y, Sun Y, Yao C. First human trial of high-frequency irreversible electroporation therapy for prostate cancer. Technol Cancer Res Treat. 2018;17:1533033818789692.
Zager Y, Kain D, Landa N, Leor J, Maor E. Optimization of irreversible electroporation protocols for in-vivo myocardial decellularization. PLoS One. 2016 Nov 28;11:e0165475.
Onik G, Mikus P, Rubinsky B. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat. 2007;6:295–300.
Neal RE, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A, vd. In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate. 2014;74:458–68.
Scheltema MJ, van den Bos W, Wagstaff PG, Postema AW, de Bruin DM, Laguna Pes MP, et al. Irreversible electroporation, a new modality in Focal Therapy for prostate cancer. Arch Esp Urol. 2016;69:337-44.
van den Bos W, Jurhill RR, de Bruin DM, Savci-Heijink CD, Postema AW, Wagstaff PGK, et al. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study. J Urol. 2016;196:552–9.
Onik G, Rubinsky B. Irreversible electroporation. Berlin, Heidelberg: Springer-Verlag; 2010. p. 235-47.
Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:343–7.
van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2018;121:716–24.
Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, et al. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021;39:1107–14.
European Association of Urology Guidelines [online]. Website https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2021V3.pdf (accessed 28.Mayıs.2021).
